- Home
- IXHL vs RLMD Comparison
IXHL vs RLMD Comparison
Compare IXHL & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- RLMD
- Stock Information
- Founded
- IXHL 2001
- RLMD 2004
- Country
- IXHL Australia
- RLMD United States
- Employees
- IXHL N/A
- RLMD N/A
- Industry
- IXHL
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- RLMD Health Care
- Exchange
- IXHL Nasdaq
- RLMD Nasdaq
- Market Cap
- IXHL 35.6M
- RLMD 37.2M
- IPO Year
- IXHL N/A
- RLMD N/A
- Fundamental
- Price
- IXHL $0.58
- RLMD $1.63
- Analyst Decision
- IXHL
- RLMD Buy
- Analyst Count
- IXHL 0
- RLMD 3
- Target Price
- IXHL N/A
- RLMD $5.00
- AVG Volume (30 Days)
- IXHL 117.4M
- RLMD 1.6M
- Earning Date
- IXHL 09-29-2025
- RLMD 11-06-2025
- Dividend Yield
- IXHL N/A
- RLMD N/A
- EPS Growth
- IXHL N/A
- RLMD N/A
- EPS
- IXHL N/A
- RLMD N/A
- Revenue
- IXHL $98,000.00
- RLMD N/A
- Revenue This Year
- IXHL $2,538.49
- RLMD N/A
- Revenue Next Year
- IXHL $249.95
- RLMD N/A
- P/E Ratio
- IXHL N/A
- RLMD N/A
- Revenue Growth
- IXHL N/A
- RLMD N/A
- 52 Week Low
- IXHL $0.08
- RLMD $0.24
- 52 Week High
- IXHL $3.12
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- IXHL 51.37
- RLMD 83.79
- Support Level
- IXHL $0.51
- RLMD $1.13
- Resistance Level
- IXHL $0.92
- RLMD $1.69
- Average True Range (ATR)
- IXHL 0.09
- RLMD 0.20
- MACD
- IXHL -0.00
- RLMD 0.11
- Stochastic Oscillator
- IXHL 37.18
- RLMD 90.87
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.